uniQure N.V. (QURE)Healthcare | Biotechnology | Amsterdam, Netherlands | NasdaqGS
41.10 USD
-1.53
(-3.589%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 41.15 +0.05 (0.122%) ⇧ (July 13, 2026, 7:46 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:24 a.m. EDT
The immediate catalyst here is the Huntington's disease therapy update, which has driven the stock up 20% recently and pushed analyst targets to $92. However, the fundamental reality remains stark: the company is burning cash with negative operating margins and negative free cash flow, trading at a forward P/E of -14. Despite the 'Strong Buy' analyst consensus, the lack of profitability and the heavy reliance on capital raises for R&D create a precarious balance sheet. The options market confirms this tension; traders are buying insurance (puts) at the $15 level while simultaneously betting on a massive surge to $70+, creating a volatile environment unsuitable for steady accumulation. While the biotech pipeline offers asymmetric upside potential if the FDA approvals materialize, the current valuation leaves little room for error. The short-term outlook is bullish due to the pending catalyst, but the long-term investment case is neutral-to-negative until the company demonstrates a path to profitability or a clear milestone-free cash runway. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.482286 |
| AutoARIMA | 0.490971 |
| AutoETS | 0.492107 |
| MSTL | 0.495026 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 6.65 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.175 |
| Excess Kurtosis | -0.59 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 365.371 |
| Revenue per Share | 0.302 |
| Market Cap | 2,825,801,472 |
| Forward P/E | -14.29 |
| Beta | 0.90 |
| Website | https://www.uniqure.com |
As of July 11, 2026, 4:24 a.m. EDT: Speculators are positioning for significant volatility rather than a specific directional breakout. Call Open Interest is heavily concentrated at the $43 strike (near ATM) and at distant strikes ($70, $90, $100), while Put Open Interest forms a massive wall at the $15 strike and another at $40-$45. This structure suggests a 'straddle' or 'strangle' strategy where traders are betting on a binary event—likely an FDA decision or clinical trial readout—rather than a steady trend. The high volume at deep out-of-the-money strikes indicates anticipation of a gap-up or gap-down move.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.9298968 |
| Address1 | Paasheuvelweg 25 |
| All Time High | 82.49 |
| All Time Low | 3.73 |
| Ask | 51.91 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,895,290 |
| Average Daily Volume3 Month | 2,196,711 |
| Average Volume | 2,196,711 |
| Average Volume10Days | 1,895,290 |
| Beta | 0.903 |
| Bid | 29.75 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 2.369 |
| City | Amsterdam |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 4 |
| Country | Netherlands |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 41.1 |
| Current Ratio | 10.402 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 42.05 |
| Day Low | 40.31 |
| Debt To Equity | 365.371 |
| Display Name | uniQure |
| Earnings Call Timestamp End | 1,777,984,200 |
| Earnings Call Timestamp Start | 1,777,984,200 |
| Earnings Timestamp | 1,777,984,200 |
| Earnings Timestamp End | 1,785,328,200 |
| Earnings Timestamp Start | 1,785,328,200 |
| Ebitda | -174,856,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -14.59 |
| Enterprise To Revenue | 141.004 |
| Enterprise Value | 2,551,179,520 |
| Eps Current Year | -3.1552 |
| Eps Forward | -2.8756075 |
| Eps Trailing Twelve Months | -3.49 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 31.9166 |
| Fifty Day Average Change | 9.183399 |
| Fifty Day Average Change Percent | 0.28773114 |
| Fifty Two Week Change Percent | 192.98969 |
| Fifty Two Week High | 71.5 |
| Fifty Two Week High Change | -30.400002 |
| Fifty Two Week High Change Percent | -0.42517483 |
| Fifty Two Week Low | 8.73 |
| Fifty Two Week Low Change | 32.37 |
| Fifty Two Week Low Change Percent | 3.7079039 |
| Fifty Two Week Range | 8.73 - 71.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,391,610,600,000 |
| Float Shares | 56,525,495 |
| Forward Eps | -2.8756075 |
| Forward P E | -14.292631 |
| Free Cashflow | -103,697,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 221 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -113,631,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01287 |
| Held Percent Institutions | 0.90202004 |
| Implied Shares Outstanding | 68,754,298 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. |
| Long Name | uniQure N.V. |
| Market | us_market |
| Market Cap | 2,825,801,472 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_171029664 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -208,868,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,930,995,723 |
| Number Of Analyst Opinions | 11 |
| Open | 41.87 |
| Operating Cashflow | -172,106,000 |
| Operating Margins | -13.211121 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Phone | 31 20 240 6000 |
| Post Market Change | 0.05000305 |
| Post Market Change Percent | 0.12166193 |
| Post Market Price | 41.15 |
| Post Market Time | 1,783,986,384 |
| Previous Close | 42.63 |
| Price Eps Current Year | -13.026115 |
| Price Hint | 2 |
| Price To Book | 17.349092 |
| Price To Sales Trailing12 Months | 156.18204 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.969 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.46154 |
| Region | US |
| Regular Market Change | -1.53 |
| Regular Market Change Percent | -3.58903 |
| Regular Market Day High | 42.05 |
| Regular Market Day Low | 40.31 |
| Regular Market Day Range | 40.31 - 42.05 |
| Regular Market Open | 41.87 |
| Regular Market Previous Close | 42.63 |
| Regular Market Price | 41.1 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,447,529 |
| Return On Assets | -0.16982001 |
| Return On Equity | -2.2823598 |
| Revenue Growth | 1.273 |
| Revenue Per Share | 0.302 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 68,754,298 |
| Shares Percent Shares Out | 0.1672 |
| Shares Short | 11,494,705 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 11,100,357 |
| Short Name | uniQure N.V. |
| Short Percent Of Float | 0.16950001 |
| Short Ratio | 3.85 |
| Source Interval | 15 |
| Symbol | QURE |
| Target High Price | 92.446465 |
| Target Low Price | 35.85763 |
| Target Mean Price | 64.533134 |
| Target Median Price | 64.504555 |
| Total Cash | 586,550,016 |
| Total Cash Per Share | 9.3 |
| Total Debt | 545,656,000 |
| Total Revenue | 18,093,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.49 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 29.56975 |
| Two Hundred Day Average Change | 11.530249 |
| Two Hundred Day Average Change Percent | 0.3899339 |
| Type Disp | Equity |
| Volume | 1,447,529 |
| Website | https://www.uniqure.com |
| Zip | 1,105 BP |